Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer - PubMed (original) (raw)
. 2009 May 20;101(10):736-50.
doi: 10.1093/jnci/djp082. Epub 2009 May 12.
Stephen K Chia, David Voduc, Dongxia Gao, Samuel Leung, Jacqueline Snider, Mark Watson, Sherri Davies, Philip S Bernard, Joel S Parker, Charles M Perou, Matthew J Ellis, Torsten O Nielsen
Affiliations
- PMID: 19436038
- PMCID: PMC2684553
- DOI: 10.1093/jnci/djp082
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
Maggie C U Cheang et al. J Natl Cancer Inst. 2009.
Abstract
Background: Gene expression profiling of breast cancer has identified two biologically distinct estrogen receptor (ER)-positive subtypes of breast cancer: luminal A and luminal B. Luminal B tumors have higher proliferation and poorer prognosis than luminal A tumors. In this study, we developed a clinically practical immunohistochemistry assay to distinguish luminal B from luminal A tumors and investigated its ability to separate tumors according to breast cancer recurrence-free and disease-specific survival.
Methods: Tumors from a cohort of 357 patients with invasive breast carcinomas were subtyped by gene expression profile. Hormone receptor status, HER2 status, and the Ki67 index (percentage of Ki67-positive cancer nuclei) were determined immunohistochemically. Receiver operating characteristic curves were used to determine the Ki67 cut point to distinguish luminal B from luminal A tumors. The prognostic value of the immunohistochemical assignment for breast cancer recurrence-free and disease-specific survival was investigated with an independent tissue microarray series of 4046 breast cancers by use of Kaplan-Meier curves and multivariable Cox regression.
Results: Gene expression profiling classified 101 (28%) of the 357 tumors as luminal A and 69 (19%) as luminal B. The best Ki67 index cut point to distinguish luminal B from luminal A tumors was 13.25%. In an independent cohort of 4046 patients with breast cancer, 2847 had hormone receptor-positive tumors. When HER2 immunohistochemistry and the Ki67 index were used to subtype these 2847 tumors, we classified 1530 (59%, 95% confidence interval [CI] = 57% to 61%) as luminal A, 846 (33%, 95% CI = 31% to 34%) as luminal B, and 222 (9%, 95% CI = 7% to 10%) as luminal-HER2 positive. Luminal B and luminal-HER2-positive breast cancers were statistically significantly associated with poor breast cancer recurrence-free and disease-specific survival in all adjuvant systemic treatment categories. Of particular relevance are women who received tamoxifen as their sole adjuvant systemic therapy, among whom the 10-year breast cancer-specific survival was 79% (95% CI = 76% to 83%) for luminal A, 64% (95% CI = 59% to 70%) for luminal B, and 57% (95% CI = 47% to 69%) for luminal-HER2 subtypes.
Conclusion: Expression of ER, progesterone receptor, and HER2 proteins and the Ki67 index appear to distinguish luminal A from luminal B breast cancer subtypes.
Figures
Figure 1
Flow diagram of the strategy for development and implementation of a breast cancer specimen classifier. A) Development with breast cancer specimens from the University of British Columbia and Washington University at St Louis (ie, the UBC-WashU series). B) Implementation or application to breast cancer specimens from the British Columbia Cancer Agency (ie, the BCCA series). ER = estrogen receptor; qRT-PCR = quantitative reverse transcription–polymerase chain reaction; IHC = immunohistochemistry; PR = progesterone receptor.
Figure 2
The x and y axes of ROC curve are true positive rate and false positive rate respectively. True positive rate equals to sensitivity and false positive rate is 1-specificity. Establishment of Ki67 cut point. True positive rate equals to sensitivity and false positive rate is 1-specificity. A) ROC analysis of 144 luminal A and B tumors with Ki67 IHC data to identify luminal B tumors as defined by a 50-gene classifier. Gene expression data for the classifier were obtained by quantitative reverse transcription–polymerase chain reaction. The selected best cut point for the Ki67 index was 13.25%. B) ROC analysis that was confined to 127 luminal A and B tumors with Spearman rank correlation coefficients of more than 0.1. CI = confidence interval; ROC = receiver operating characteristic; IHS = immunohistochemistry.
Figure 3
Univariate survival by breast cancer subtype among 943 patients with lymph node–negative, hormone receptor–positive breast cancer who received no adjuvant systemic therapy. A) Relapse-free survival. B) Breast cancer–specific survival. CI = confidence interval.
Figure 4
Univariate survival by breast cancer subtype among 976 patients with hormone receptor–positive breast cancer who received tamoxifen as their sole adjuvant systemic therapy. A) Relapse-free survival among all 976 patients. B) Breast cancer–specific survival among all 974 patients (two patients with unknown cause of death were excluded). C) Relapse-free survival among 287 patients with lymph node–negative disease. D) Breast cancer–specific survival among 287 patients with lymph node–negative disease. E) Relapse-free survival among 627 patients with lymph node–positive disease. F) Breast cancer–specific survival among 625 patients with lymph node–positive disease (two patients with unknown cause of death were excluded). CI = confidence interval.
Figure 5
Univariate survival by breast cancer subtype among 196 patients with hormone receptor–positive breast cancer who were treated with both tamoxifen and chemotherapy (doxorubicin and cyclophosphamide; fluorouracil, doxorubicin, and cyclophosphamide; or cyclophosphamide, methotrexate, and fluorouracil) as adjuvant systemic treatments. A) Relapse-free survival. B) Breast cancer–specific survival. CI = confidence interval.
Comment in
- Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Howell SJ, Wardley AM, Armstrong AC. Howell SJ, et al. J Natl Cancer Inst. 2009 Dec 16;101(24):1730; author reply 1730-1. doi: 10.1093/jnci/djp390. J Natl Cancer Inst. 2009. PMID: 19893007 No abstract available.
Similar articles
- High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, Imamura M, Takatsuka Y, Sakita I, Hatada T, Miyoshi Y. Nishimukai A, et al. Clin Breast Cancer. 2015 Jun;15(3):204-11. doi: 10.1016/j.clbc.2014.12.007. Epub 2014 Dec 24. Clin Breast Cancer. 2015. PMID: 25600243 - Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS, Lænkholm AV, Jensen MB, Nielsen KV, Andersen J, Nielsen D, Ejlertsen B; Danish Breast Cancer Cooperative Group. Knoop AS, et al. Eur J Cancer. 2014 May;50(8):1412-21. doi: 10.1016/j.ejca.2014.02.022. Epub 2014 Mar 24. Eur J Cancer. 2014. PMID: 24675287 Clinical Trial. - Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G, Guaineri A, Bianchi A, Amoroso V, Pasinetti N, Pasini M. Pata G, et al. J Surg Res. 2019 Apr;236:288-299. doi: 10.1016/j.jss.2018.11.028. Epub 2018 Dec 27. J Surg Res. 2019. PMID: 30694768 - Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS. Guiu S, et al. Ann Oncol. 2012 Dec;23(12):2997-3006. doi: 10.1093/annonc/mds586. Ann Oncol. 2012. PMID: 23166150 Review. - Histology of Luminal Breast Cancer.
Erber R, Hartmann A. Erber R, et al. Breast Care (Basel). 2020 Aug;15(4):327-336. doi: 10.1159/000509025. Epub 2020 Jul 15. Breast Care (Basel). 2020. PMID: 32982642 Free PMC article. Review.
Cited by
- Formononetin triggers ferroptosis in triple-negative breast cancer cells by regulating the mTORC1/SREBP1/SCD1 pathway.
Xie D, Jiang Y, Wang H, Zhu L, Huang S, Liu S, Zhang W, Li T. Xie D, et al. Front Pharmacol. 2024 Sep 27;15:1441105. doi: 10.3389/fphar.2024.1441105. eCollection 2024. Front Pharmacol. 2024. PMID: 39399463 Free PMC article. - Breast cancer molecular subtype classification according to immunohistochemistry markers and its association with pathological characteristics among women attending tertiary hospitals in Tanzania.
Ismail A, Panjwani S, Ismail N, Ngimba C, Mosha I, Adebayo P, Mwanga A, Zehri AA, Njau A, Athar A. Ismail A, et al. Heliyon. 2024 Sep 26;10(19):e38493. doi: 10.1016/j.heliyon.2024.e38493. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39398050 Free PMC article. - Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer.
Sarangi P. Sarangi P. Cancer Pathog Ther. 2023 Nov 7;2(4):246-255. doi: 10.1016/j.cpt.2023.11.001. eCollection 2024 Oct. Cancer Pathog Ther. 2023. PMID: 39371092 Free PMC article. Review. - Isoform-Level Transcriptome Analysis of Peripheral Blood Mononuclear Cells from Breast Cancer Patients Identifies a Disease-Associated RASGEF1A Isoform.
Čelešnik H, Gorenjak M, Krušič M, Crnobrnja B, Sobočan M, Takač I, Arko D, Potočnik U. Čelešnik H, et al. Cancers (Basel). 2024 Sep 16;16(18):3171. doi: 10.3390/cancers16183171. Cancers (Basel). 2024. PMID: 39335143 Free PMC article. - Risk of locoregional recurrence after breast cancer surgery by molecular subtype-a systematic review and network meta-analysis.
Nolan L, Davey MG, Calpin GG, Ryan ÉJ, Boland MR. Nolan L, et al. Ir J Med Sci. 2024 Sep 27. doi: 10.1007/s11845-024-03809-z. Online ahead of print. Ir J Med Sci. 2024. PMID: 39331262 Review.
References
- Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. - PubMed
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. - PubMed
- Tamoxifen for early breast canceran overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;351(9114):1451–1467. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous